AIMS/HYPOTHESIS: We aimed to investigate the risk of cancer mortality in relation to the glucose tolerance status classified according to the 2 h OGTT. METHODS: Data from 17 European population-based or occupational cohorts involved in the DECODE study comprising 26,460 men and 18,195 women aged 25-90 years were collaboratively analysed. The cohorts were recruited between 1966 and 2004 and followed for 5.9 to 36.8 years. Cox proportional hazards analysis with adjustment for cohort, age, BMI, total cholesterol, blood pressure and smoking status was used to estimate HRs for cancer mortality. RESULTS: Compared with people in the normal glucose category, multivariable adjusted HRs (95% CI) for cancer mortality were 1.13 (1.00, 1.28), 1.27 (1.02, 1.57) and 1.71 (1.35, 2.17) in men with prediabetes, previously undiagnosed diabetes and known diabetes, respectively; in women they were 1.11 (0.94, 1.30), 1.31 (1.00, 1.70) and 1.43 (1.01, 2.02), respectively. Significant increases in deaths from cancer of the stomach, colon-rectum and liver in men with prediabetes and diabetes, and deaths from cancers of the liver and pancreas in women with diabetes were also observed. In individuals without known diabetes, the HR (95% CI) for cancer mortality corresponding to a one standard deviation increase in fasting plasma glucose was 1.06 (1.02, 1.09) and in 2 h plasma glucose was 1.07 (1.03, 1.11). CONCLUSIONS/ INTERPRETATION: Diabetes and prediabetes were associated with an increased risk of cancer death, particularly death from liver cancer. Mortality from all cancers rose linearly with increasing glucose concentrations.
AIMS/HYPOTHESIS: We aimed to investigate the risk of cancer mortality in relation to the glucose tolerance status classified according to the 2 h OGTT. METHODS: Data from 17 European population-based or occupational cohorts involved in the DECODE study comprising 26,460 men and 18,195 women aged 25-90 years were collaboratively analysed. The cohorts were recruited between 1966 and 2004 and followed for 5.9 to 36.8 years. Cox proportional hazards analysis with adjustment for cohort, age, BMI, total cholesterol, blood pressure and smoking status was used to estimate HRs for cancer mortality. RESULTS: Compared with people in the normal glucose category, multivariable adjusted HRs (95% CI) for cancer mortality were 1.13 (1.00, 1.28), 1.27 (1.02, 1.57) and 1.71 (1.35, 2.17) in men with prediabetes, previously undiagnosed diabetes and known diabetes, respectively; in women they were 1.11 (0.94, 1.30), 1.31 (1.00, 1.70) and 1.43 (1.01, 2.02), respectively. Significant increases in deaths from cancer of the stomach, colon-rectum and liver in men with prediabetes and diabetes, and deaths from cancers of the liver and pancreas in women with diabetes were also observed. In individuals without known diabetes, the HR (95% CI) for cancer mortality corresponding to a one standard deviation increase in fasting plasma glucose was 1.06 (1.02, 1.09) and in 2 h plasma glucose was 1.07 (1.03, 1.11). CONCLUSIONS/ INTERPRETATION:Diabetes and prediabetes were associated with an increased risk of cancer death, particularly death from liver cancer. Mortality from all cancers rose linearly with increasing glucose concentrations.
Authors: N Unwin; J Harland; M White; R Bhopal; P Winocour; P Stephenson; W Watson; C Turner; K G Alberti Journal: J Epidemiol Community Health Date: 1997-04 Impact factor: 3.710
Authors: G Berglund; P Nilsson; K F Eriksson; J A Nilsson; B Hedblad; H Kristenson; F Lindgärde Journal: J Intern Med Date: 2000-01 Impact factor: 8.989
Authors: M P Garancini; G Calori; G Ruotolo; E Manara; A Izzo; E Ebbli; A M Bozzetti; L Boari; P Lazzari; G Gallus Journal: Diabetologia Date: 1995-03 Impact factor: 10.122
Authors: Steven S Coughlin; Eugenia E Calle; Lauren R Teras; Jennifer Petrelli; Michael J Thun Journal: Am J Epidemiol Date: 2004-06-15 Impact factor: 4.897
Authors: J H Stengård; J Tuomilehto; J Pekkanen; P Kivinen; E Kaarsalo; A Nissinen; M J Karvonen Journal: Diabetologia Date: 1992-08 Impact factor: 10.122
Authors: Lorenzo Scappaticcio; Maria Ida Maiorino; Giuseppe Bellastella; Dario Giugliano; Katherine Esposito Journal: Endocrine Date: 2016-12-31 Impact factor: 3.633
Authors: Max Dieterich; Johannes Stubert; Toralf Reimer; Nicole Erickson; Anika Berling Journal: Breast Care (Basel) Date: 2014-12 Impact factor: 2.860
Authors: Kirsten Erickson; Ruth E Patterson; Shirley W Flatt; Loki Natarajan; Barbara A Parker; Dennis D Heath; Gail A Laughlin; Nazmus Saquib; Cheryl L Rock; John P Pierce Journal: J Clin Oncol Date: 2010-11-29 Impact factor: 44.544
Authors: Suzanne G Orchard; Jessica E Lockery; Peter Gibbs; Galina Polekhina; Rory Wolfe; John Zalcberg; Andrew Haydon; John J McNeil; Mark R Nelson; Christopher M Reid; Brenda Kirpach; Anne M Murray; Robyn L Woods Journal: Contemp Clin Trials Date: 2020-07-31 Impact factor: 2.226